Cyltezo, adalimumab biosimilar from Boehringer Ingelheim, approved in E
The European Commission has granted marketing authorisation for a biosimilar...
2017-11-15
文传商讯
Efficacy and safety maintained in patients who switched from Humira to
48-week Phase III data showed Cyltezo® and Humira® have similar effi...
2017-11-08
文传商讯
